2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance
Key Takeaways
- Renal blood flow (RBF) is approximately 1,200 mL/min (20-25% of resting cardiac output) with autoregulation maintaining constant RBF and GFR between a mean arterial pressure (MAP) of 80 and 180 mmHg; below 80 mmHg, GFR declines linearly and ceases below 50 mmHg.
- Glomerular hemodynamics depend on opposing vascular controls: Angiotensin II preferentially constricts the efferent arteriole to sustain GFR during hypoperfusion, while prostaglandins dilate the afferent arteriole (blocked by NSAIDs, inducing prerenal AKI).
- Serum anion gap is calculated as [Na+] - ([Cl-] + [HCO3-]) with normal values of 8-12 mEq/L; in hypoalbuminemia, the normal expected anion gap decreases by 2.5 mEq/L for every 1 g/dL decline in serum albumin below 4.0 g/dL.
- Winter's formula evaluates respiratory compensation in metabolic acidosis: Expected PaCO2 = (1.5 x [HCO3-]) + 8 +/- 2; measured PaCO2 above expected indicates a concomitant respiratory acidosis, while PaCO2 below expected indicates a concurrent respiratory alkalosis.
- KDIGO AKI Stage 1 is defined by a serum creatinine rise >=0.3 mg/dL within 48 hours or 1.5-1.9x baseline, or urine output <0.5 mL/kg/h for 6-12 hours; prerenal azotemia features a BUN:Cr ratio >20:1, FENa <1%, and urine osmolality >500 mOsm/kg.
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance
Mastery of renal physiology, glomerular filtration hemodynamics, neurohormonal regulation, acid-base calculations, and acute kidney injury (AKI) classification is essential for the certified registered nurse anesthetist (CRNA). General and regional anesthesia profoundly influence renal blood flow (RBF) and tubular handling of electrolytes and water. Furthermore, pre-existing renal disease alters the pharmacokinetics and pharmacodynamics of induction hypnotics, muscle relaxants, and analgesics.
1. Functional Nephron Anatomy & Segmental Tubular Physiology
The kidneys receive approximately 20% to 25% of resting cardiac output (~1,200 mL/min), representing the highest tissue perfusion rate per gram of tissue in the body. The functional unit of the kidney is the nephron, comprising approximately 1 to 1.2 million units per kidney. Nephrons are divided into cortical nephrons (~85%, located in the outer cortex with short loops of Henle) and juxtamedullary nephrons (~15%, located at the corticomedullary junction with long loops of Henle extending deep into the hypertonic renal medulla, essential for generating concentrated urine via countercurrent multiplication).
Glomerulus / Bowman's Space (Filtration: 125 mL/min)
│
▼
Proximal Convoluted Tubule (PCT)
• 65-70% Na+, H2O, K+, Cl- reabsorption
• 100% glucose (threshold 180-200 mg/dL) & amino acids
• 85-90% HCO3- reabsorption (carbonic anhydrase dependent)
• Iso-osmotic reabsorption (~300 mOsm/kg)
│
▼
Loop of Henle
• Descending Thin Limb: Highly permeable to H2O (aquaporin-1), impermeable to solutes (luminal fluid concentrates to ~1200 mOsm/kg at hairpin)
• Ascending Thin Limb: Impermeable to H2O, permeable to NaCl
• Thick Ascending Limb (TAL): Impermeable to H2O; active Na+/K+/2Cl- cotransporter (NKCC2; blocked by loop diuretics); generates medullary hypertonicity
│
▼
Distal Convoluted Tubule (DCT)
• Early DCT: Impermeable to H2O (cortical diluting segment); Na+/Cl- cotransporter (NCCT; blocked by thiazides); PTH-stimulated active Ca2+ reabsorption
• Hypo-osmotic luminal fluid (~100 mOsm/kg)
│
▼
Collecting Duct (Late DCT & Medullary Collecting Duct)
• Principal Cells: ENaC channels (Na+ reabsorption), ROMK (K+ secretion), regulated by Aldosterone; Aquaporin-2 water channels inserted by ADH (V2 receptor / cAMP)
• Type A Intercalated Cells: Active H+-ATPase & H+/K+-ATPase (acid secretion, HCO3- reabsorption in acidosis)
• Type B Intercalated Cells: Pendrin (Cl-/HCO3- exchanger; HCO3- secretion, H+ reabsorption in alkalosis)
Segmental Transport Mechanisms & Diuretic Targets
| Nephron Segment | Major Transporters & Channels | Primary Solutes Reabsorbed / Secreted | Hormonal Regulation | Diuretic Drug Class & Site of Action |
|---|---|---|---|---|
| Proximal Tubule (PCT) | Na+/H+ antiporter (NHE3), Na+/Glucose cotransporters (SGLT2/SGLT1), Carbonic Anhydrase (CA IV / CA II) | Reabsorbs: 65% Na+/H2O, 100% Glucose, 85-90% HCO3-, Amino acids, Phosphate, K+ | Angiotensin II (stimulates NHE3), Parathyroid Hormone (inhibits Na+/PO4 cotransporter) | Carbonic Anhydrase Inhibitors (Acetazolamide; blocks HCO3- reabsorption, produces alkaline diuresis) |
| Thick Ascending Limb (TAL) | Na+/K+/2Cl- cotransporter (NKCC2), ROMK channel (K+ back-leak creates +8 mV lumen-positive transepithelial potential driving paracellular Ca2+/Mg2+ reabsorption) | Reabsorbs: 25% Na+, 25% K+, 25% Cl-, Ca2+, Mg2+; Impermeable to water | Prostaglandins, Calcium-sensing receptor (CaSR) | Loop Diuretics (Furosemide, Bumetanide, Torsemide; inhibit NKCC2, abolish medullary hypertonicity, cause profound diuresis and Ca2+/Mg2+ wasting) |
| Distal Convoluted Tubule (DCT) | Na+/Cl- cotransporter (NCCT), Apical TRPV5 Ca2+ channel, Basolateral Na+/Ca2+ exchanger (NCX1) | Reabsorbs: 5-7% Na+, Cl-, Ca2+; Impermeable to water | Parathyroid Hormone (PTH; upregulates TRPV5 to increase Ca2+ reabsorption), Aldosterone | Thiazide Diuretics (Hydrochlorothiazide, Chlorthalidone; inhibit NCCT, increase distal Ca2+ reabsorption) |
| Cortical & Medullary Collecting Duct | Principal cells: ENaC (epithelial Na+ channel), ROMK; Intercalated cells: H+-ATPase, H+/K+-ATPase, Pendrin | Principal cells: Reabsorbs 2-5% Na+, secretes K+; Intercalated cells: Secretes H+ or HCO3- | Aldosterone (upregulates ENaC & basolateral Na+/K+-ATPase), ADH / Vasopressin (inserts Aquaporin-2), ANP/BNP (inhibits Na+ reabsorption) | Potassium-Sparing Diuretics (Spironolactone/Eplerenone: mineralocorticoid receptor antagonists; Amiloride/Triamterene: direct ENaC blockers) |
2. Glomerular Filtration Rate & Renal Autoregulation
Determinants of Glomerular Filtration
Glomerular Filtration Rate (GFR) averages 125 mL/min in healthy young adults (~180 L/day). Filtration is governed by Starling forces across the glomerular capillary wall:
- $K_f$ = Glomerular ultrafiltration coefficient (surface area $\times$ hydraulic permeability).
- $P_{\text{GC}}$ = Glomerular capillary hydrostatic pressure (~50-60 mmHg; favors filtration; regulated by afferent and efferent arteriolar tone).
- $P_{\text{BS}}$ = Bowman's space hydrostatic pressure (~15 mmHg; opposes filtration; elevated in ureteral obstruction).
- $\Pi_{\text{GC}}$ = Glomerular capillary oncotic pressure (~25 mmHg at afferent end, rising to ~35 mmHg at efferent end; opposes filtration).
- $\Pi_{\text{BS}}$ = Bowman's space oncotic pressure (~0 mmHg in healthy glomeruli).
- Filtration Fraction (FF): $\text{FF} = \frac{\text{GFR}}{\text{RPF}} \approx \frac{125\text{ mL/min}}{625\text{ mL/min}} \approx 20%$.
Renal Autoregulation: Mechanisms & Limits
Renal autoregulation maintains a relatively constant Renal Blood Flow (RBF) and GFR across a Mean Arterial Pressure (MAP) range of 80 to 180 mmHg (or perfusion pressures of 75-160 mmHg).
Renal Perfusion Pressure (MAP 80 - 180 mmHg)
├── 1. Myogenic Response (Fast, 1-3 seconds):
│ Elevated transmural stretch on afferent arteriolar smooth muscle
│ → Opens stretch-activated non-selective cation channels
│ → Membrane depolarization & voltage-gated Ca2+ entry (L-type)
│ → Immediate afferent arteriolar constriction (prevents hyperfiltration)
│
└── 2. Tubuloglomerular Feedback (TGF; 10-30 seconds):
Elevated GFR / RBF → Increased NaCl delivery to Macula Densa (TAL)
→ Increased NKCC2 transport of Na+/K+/2Cl- into macula densa cells
→ Basolateral ATP and Adenosine release
→ Binds Adenosine A1 receptors on afferent arteriolar smooth muscle
→ Afferent arteriolar vasoconstriction & inhibition of renin release
AUTOREGULATION WINDOW
RBF / GFR │ ____________________
(mL/min) │ / \
│ / \
│ / \
│ / \
│ / \
└────────────┴──────────────────────────────┴──────────
0 80 180 MAP (mmHg)
[Linear Drop] [Glomerular Protection] [Pressure Diuresis]
NCE Clinical Pearl — The MAP Thresholds:
- MAP 80–180 mmHg: Autoregulation active; GFR and RBF are held constant.
- MAP < 80 mmHg: Autoregulation is exhausted; RBF and GFR decline linearly with further reductions in perfusion pressure.
- MAP < 50 mmHg: Glomerular capillary hydrostatic pressure ($P_{\text{GC}}$) drops below opposing oncotic and Bowman's pressures; glomerular ultrafiltration ceases entirely, resulting in acute anuria.
Afferent vs. Efferent Arteriolar Control & Pharmacologic Traps
Glomerular capillary pressure ($P_{\text{GC}}$) and GFR are precisely tuned by modulating pre-glomerular (afferent) versus post-glomerular (efferent) arteriolar resistance:
| Vascular Bed | Primary Mediators | Effect on Resistance | Effect on Glomerular Pressure ($P_{\text{GC}}$) | Effect on GFR | Effect on RBF | Anesthetic & Pharmacologic Implications |
|---|---|---|---|---|---|---|
| Afferent Arteriole | Constriction: Endothelin, Norepinephrine, Thromboxane A2, High-dose Dopamine, TGF (Adenosine via A1) | $\uparrow R_A$ | $\downarrow P_{\text{GC}}$ | $\downarrow$ GFR | $\downarrow$ RBF | Severe sympathetic surge / alpha-1 agonists decrease GFR. |
| Afferent Arteriole | Dilation: Prostaglandins (PGE2, PGI2), Nitric Oxide (NO), Low-dose Dopamine, ANP/BNP | $\downarrow R_A$ | $\uparrow P_{\text{GC}}$ | $\uparrow$ GFR | $\uparrow$ RBF | NSAIDs (Ketorolac, Ibuprofen): Inhibit COX-1/2, blocking PGE2 synthesis $\rightarrow$ unchecked afferent vasoconstriction $\rightarrow$ acute precipitous drop in GFR (prerenal AKI). |
| Efferent Arteriole | Constriction: Angiotensin II (AT1 receptors, preferential low-dose effect) | $\uparrow R_E$ | $\uparrow P_{\text{GC}}$ | $\uparrow$ GFR (or preserved) | $\downarrow$ RBF | Sustains GFR during low-flow/hypovolemic states by raising post-capillary resistance. |
| Efferent Arteriole | Dilation: ACE inhibitors (Lisinopril, Enalaprilat), ARBs (Losartan), AT1 receptor blockers | $\downarrow R_E$ | $\downarrow P_{\text{GC}}$ | $\downarrow$ GFR | $\uparrow$ RBF | ACEi / ARB Trap: Abolishes Angiotensin II efferent constriction $\rightarrow$ efferent vasodilation $\rightarrow$ profound loss of $P_{\text{GC}}$ and acute drop in GFR during intraoperative hypotension. |
3. Neurohormonal Control: RAAS Cascade, Aldosterone & ADH
THE RAAS CASCADE
Renal Hypoperfusion (MAP <80 mmHg) │ Decreased NaCl to Macula Densa │ Beta-1 Adrenergic Surge
────────────────────────────────────┼──────────────────────────────────┼─────────────────────────
▼
Juxtaglomerular (JG) Granular Cells
│
▼ Secretes
RENIN (Enzyme)
│
Angiotensinogen (Liver) ────┴────► ANGIOTENSIN I (Decapeptide)
│
Pulmonary Endothelium (ACE) ──┴──► ANGIOTENSIN II (Octapeptide)
│
┌───────────────────────┬────────────────────────┬───────┴────────────────────────┐
▼ ▼ ▼ ▼
Potent Systemic Preferential Efferent Zona Glomerulosa (Adrenal) Hypothalamus / Pituitary
Vasoconstriction (AT1) Arteriolar Constriction • Secretes ALDOSTERONE • Stimulates ADH release
(Increases SVR & MAP) (Preserves GFR) • Na+ reabsorption / K+ excretion • Stimulates Thirst drive
ADH (Vasopressin) vs. Aldosterone: Key Distinctions
| Feature | Aldosterone | Antidiuretic Hormone (ADH / Arginine Vasopressin) |
|---|---|---|
| Synthesis & Secretion Site | Adrenal Cortex (Zona Glomerulosa); steroid hormone | Synthesized in Supraoptic & Paraventricular nuclei of Hypothalamus; stored and released from Posterior Pituitary |
| Primary Stimuli | Angiotensin II, Hyperkalemia (direct adrenal sensing), ACTH, Hyponatremia | Increased Plasma Osmolality (1-2% rise sensed by hypothalamic osmoreceptors); Hypovolemia / Hypotension (5-10% drop sensed by carotid/aortic baroreceptors) |
| Receptor & Intracellular Pathway | Nuclear Mineralocorticoid Receptor (MR) $\rightarrow$ gene transcription of ENaC, ROMK, and Na+/K+-ATPase | V2 Receptors on basolateral membrane of principal cells $\rightarrow$ $G_s \rightarrow$ Adenylate Cyclase $\rightarrow$ cAMP $\rightarrow$ PKA $\rightarrow$ Aquaporin-2 vesicle exocytosis; V1a Receptors on vascular smooth muscle $\rightarrow$ $G_q \rightarrow$ IP3/DAG/Ca2+ $\rightarrow$ vasoconstriction |
| Renal Handling Effect | Reabsorbs $\text{Na}^+$ and $\text{H}_2\text{O}$ iso-osmotically; secretes $\text{K}^+$ and $\text{H}^+$ | Reabsorbs free, solute-free water exclusively via Aquaporin-2 channels in collecting duct |
| Urine & Plasma Osmolality Impact | Increases effective circulating volume; minimal direct effect on plasma tonicity | Concentrates urine (up to 1,200 mOsm/kg), dilutes plasma (lowers plasma sodium and osmolality) |
| Pathologic Derangements | Conn's Syndrome (primary hyperaldosteronism: HTN, hypokalemia, metabolic alkalosis); Addison's Disease (hypoaldosteronism: hypotension, hyperkalemia, metabolic acidosis) | SIADH (euvolemic hyponatremia, high urine osmolality >100 mOsm/kg, urine Na+ >40 mEq/L); Diabetes Insipidus (hypernatremia, polyuria, low urine osmolality <300 mOsm/kg) |
4. Acid-Base Physiology & Clinical Calculations
Henderson-Hasselbalch Formulation
The fundamental equation describing the bicarbonate buffer system:
- The ratio of $[\text{HCO}_3^-]$ to $(0.03 \times \text{PaCO}_2)$ is normally 20:1. Any process altering this ratio shifts blood pH away from 7.40.
Primary Acid-Base Disturbances & Expected Compensation Formulas
| Primary Disturbance | Primary Defect | Secondary Compensatory Response | Formula for Expected Compensation |
|---|---|---|---|
| Metabolic Acidosis | $\downarrow [\text{HCO}_3^-]$ | Hyperventilation ($\downarrow \text{PaCO}_2$) | Winter's Formula: $\text{Expected PaCO}_2 = (1.5 \times [\text{HCO}_3^-]) + 8 \pm 2$ |
| Metabolic Alkalosis | $\uparrow [\text{HCO}_3^-]$ | Hypoventilation ($\uparrow \text{PaCO}_2$) | $\text{Expected PaCO}_2 = (0.7 \times [\text{HCO}_3^-]) + 20 \pm 5$ (or $\text{PaCO}_2$ rises 0.7 mmHg per 1 mEq/L rise in $\text{HCO}_3^-$) |
| Acute Respiratory Acidosis | $\uparrow \text{PaCO}_2$ | Cellular buffering (slight $\uparrow [\text{HCO}_3^-]$) | For every $10\text{ mmHg} \uparrow \text{PaCO}_2$: $[\text{HCO}_3^-] \uparrow 1\text{ mEq/L}$; $\text{pH} \downarrow 0.08$ |
| Chronic Respiratory Acidosis | $\uparrow \text{PaCO}_2$ | Renal $\text{HCO}_3^-$ retention (3-5 days) | For every $10\text{ mmHg} \uparrow \text{PaCO}_2$: $[\text{HCO}_3^-] \uparrow 3.5\text{ to }4.0\text{ mEq/L}$; $\text{pH} \downarrow 0.03$ |
| Acute Respiratory Alkalosis | $\downarrow \text{PaCO}_2$ | Cellular buffering (slight $\downarrow [\text{HCO}_3^-]$) | For every $10\text{ mmHg} \downarrow \text{PaCO}_2$: $[\text{HCO}_3^-] \downarrow 2\text{ mEq/L}$; $\text{pH} \uparrow 0.08$ |
| Chronic Respiratory Alkalosis | $\downarrow \text{PaCO}_2$ | Renal $\text{HCO}_3^-$ excretion (3-5 days) | For every $10\text{ mmHg} \downarrow \text{PaCO}_2$: $[\text{HCO}_3^-] \downarrow 4.0\text{ to }5.0\text{ mEq/L}$; $\text{pH} \uparrow 0.03$ |
Anion Gap & Delta Calculations
Serum Anion Gap (AG) = [Na+] - ([Cl-] + [HCO3-])
Normal Range: 8 to 12 mEq/L (mean ~10 mEq/L)
- Correction for Hypoalbuminemia: Serum albumin is the major unmeasured anion (~2.5 mEq/L per 1 g/dL albumin). For every 1.0 g/dL drop in serum albumin below 4.0 g/dL, the normal expected baseline Anion Gap decreases by 2.5 mEq/L:
-
Differential Diagnosis of Metabolic Acidosis:
- High Anion Gap Metabolic Acidosis (HAGMA - "GOLD MARK"): Glycols (ethylene/propylene), Oxoproline (chronic acetaminophen), L-Lactate (sepsis, shock, hypoperfusion), D-Lactate (short bowel syndrome), Methanol, Aspirin (salicylates), Renal failure (uremia, sulfate/phosphate retention), Ketoacidosis (diabetic, alcoholic, starvation).
- Normal Anion Gap / Hyperchloremic Metabolic Acidosis (NAGMA - "USEDCARP"): Ureterosigmoidostomy, Saline (0.9% NaCl resuscitation), Enteric loss (diarrhea), Drugs (Acetazolamide), Carbonic anhydrase inhibitors, Addison's disease, Renal Tubular Acidosis (Types 1, 2, 4), Pancreatic fistula.
-
Delta-Delta ($\Delta-\Delta$) Ratio: Evaluates for mixed acid-base disorders in the presence of a HAGMA:
- $\text{Delta Ratio} = 1.0\text{ to }2.0$: Pure High Anion Gap Metabolic Acidosis.
- $\text{Delta Ratio} < 1.0$ (or $<0.8$): Mixed HAGMA and Normal Anion Gap (Hyperchloremic) Metabolic Acidosis (e.g., DKA treated with massive 0.9% normal saline, or lactic acidosis plus severe diarrhea).
- $\text{Delta Ratio} > 2.0$: Mixed HAGMA and Metabolic Alkalosis (e.g., DKA or lactic acidosis with concomitant nasogastric suctioning or vomiting) or pre-existing compensated chronic respiratory acidosis.
5. Acute Kidney Injury: RIFLE & KDIGO Criteria
Acute Kidney Injury (AKI) is an abrupt decline in renal function occurring over hours to days, resulting in nitrogenous waste retention (azotemia) and dysregulation of extracellular volume and electrolytes.
KDIGO Staging System for AKI
| KDIGO Stage | Serum Creatinine (SCr) Criteria | Urine Output (UO) Criteria |
|---|---|---|
| Stage 1 | $\uparrow$ SCr $\ge 0.3\text{ mg/dL}$ within 48 hours, OR $\uparrow$ SCr $1.5\text{ to }1.9\times$ baseline within 7 days | $< 0.5\text{ mL/kg/h}$ for 6 to 12 hours |
| Stage 2 | $\uparrow$ SCr $2.0\text{ to }2.9\times$ baseline within 7 days | $< 0.5\text{ mL/kg/h}$ for $\ge 12\text{ hours}$ |
| Stage 3 | $\uparrow$ SCr $3.0\times$ baseline within 7 days, OR $\uparrow$ SCr $\ge 4.0\text{ mg/dL}$, OR initiation of Renal Replacement Therapy (RRT), OR in patients $<18$ years: $\downarrow$ eGFR $< 35\text{ mL/min}/1.73\text{m}^2$ | $< 0.3\text{ mL/kg/h}$ for $\ge 24\text{ hours}$, OR Anuria for $\ge 12\text{ hours}$ |
Prerenal Azotemia vs. Intrinsic Acute Tubular Necrosis (ATN)
| Diagnostic Parameter | Prerenal Azotemia (Hypoperfusion) | Intrinsic AKI (Acute Tubular Necrosis) | Physiologic Rationale |
|---|---|---|---|
| BUN / Serum Creatinine Ratio | $> 20:1$ | $< 15:1$ | Urea is passively reabsorbed alongside enhanced proximal $\text{Na}^+$ and $\text{H}_2\text{O}$ reabsorption in hypoperfusion; creatinine is not. |
| Fractional Excretion of $\text{Na}^+$ ($\text{FENa}$) | $< 1.0%$ | $> 2.0%$ | $\text{FENa} = \frac{U_{\text{Na}} \times S_{\text{Cr}}}{S_{\text{Na}} \times U_{\text{Cr}}} \times 100%$. Intact tubules avidly reabsorb sodium in prerenal; necrotic tubular epithelial cells lose reabsorptive capacity in ATN. |
| Fractional Excretion of Urea ($\text{FEUrea}$) | $< 35%$ | $> 50%$ | Use when patient has received loop diuretics (which artificially elevate urine sodium and invalidate $\text{FENa}$). |
| Urine Sodium ($U_{\text{Na}}$) | $< 20\text{ mEq/L}$ | $> 40\text{ mEq/L}$ | Avid sodium retention in intact nephrons vs. tubular salt-wasting. |
| Urine Osmolality | $> 500\text{ mOsm/kg}$ | $< 350\text{ mOsm/kg}$ (Isosthenuric) | Intact collecting ducts concentrate urine under maximal ADH stimulation vs. loss of medullary concentrating gradient. |
| Urine Specific Gravity | $> 1.020$ | $\sim 1.010$ | Reflects concentrated vs. dilute/isosthenuric tubular fluid. |
| Urine Sediment Microscopy | Normal, or transparent Hyaline Casts | "Muddy brown" granular casts, renal tubular epithelial (RTE) cells | Sloughed necrotic tubular epithelial cells and cellular debris forming pigmented granular cylinders. |
6. Anesthetic Effects on Renal Hemodynamics & Pharmacology
Impact of Anesthetic Agents & Positive Pressure Ventilation
- Inhalation Anesthetics & IV Hypnotics:
- Volatile agents (Sevoflurane, Desflurane, Isoflurane) and IV induction agents (Propofol) cause dose-dependent myocardial depression and systemic vasodilation $\rightarrow$ decrease MAP and cardiac output $\rightarrow$ indirect reduction in RBF, GFR, and urine output.
- Autoregulation curve shifts rightward during deep anesthesia, narrowing the protective autoregulatory window.
- Mechanical Positive Pressure Ventilation & PEEP:
- Increased intrathoracic pressure $\rightarrow$ decreases venous return (preload) and right ventricular stroke volume $\rightarrow$ decreases cardiac output.
- Stimulates arterial baroreceptors and atrial stretch receptors $\rightarrow$ triggers sympathetic activation, RAAS stimulation, and non-osmotic ADH release $\rightarrow$ leads to oliguria and renal vasoconstriction.
- Sevoflurane, Compound A & Fluoride Nephrotoxicity:
- Compound A (Fluoromethyl-2,2-difluoro-1-[trifluoromethyl]vinyl ether): Formed when Sevoflurane reacts with strong base carbon dioxide absorbents (potassium hydroxide $\text{KOH}$ or sodium hydroxide $\text{NaOH}$) found in dry soda lime or Baralyme. Produces proximal tubular necrosis in Wistar rats.
- FDA Recommendation: Maintain fresh gas flow (FGF) $\ge 1\text{ L/min}$ for procedures lasting up to 2 hours, and $\ge 2\text{ L/min}$ for procedures $>2\text{ hours}$ to prevent Compound A accumulation. Modern absorbents (Amsorb, calcium hydroxide without strong bases) eliminate Compound A formation.
- Inorganic Fluoride ($F^-$): Sevoflurane undergoes ~2-5% hepatic CYP2E1 metabolism releasing fluoride ions. Unlike Methoxyflurane (which produced vasopressin-resistant polyuric renal failure at serum $F^- > 50\ \mu\text{mol/L}$ due to extensive intra-renal metabolism), Sevoflurane does not cause nephrogenic diabetes insipidus because it is rapidly cleared via the lungs and lacks intra-renal bioactivation.
Anesthetic Drug Clearance in Renal Impairment
| Anesthetic Agent | Route of Elimination | Active / Toxic Metabolites | Clinical Recommendation in End-Stage Renal Disease (ESRD) |
|---|---|---|---|
| Succinylcholine | Plasma Butyrylcholinesterase (Pseudocholinesterase) | None (Succinylmonocholine has $<1%$ activity) | Causes predictable $0.5\text{ mEq/L}$ rise in serum $\text{K}^+$. Safe in ESRD if baseline $\text{K}^+ \le 5.5\text{ mEq/L}$ and no denervation injury (burns, stroke, spinal cord transection). |
| Cisatracurium & Atracurium | Hofmann Elimination (spontaneous non-enzymatic degradation at physiologic pH and temperature) + non-specific ester hydrolysis | Laudanosine (CNS stimulant, epileptogenic at massive levels; clinically insignificant) | Neuromuscular blockers of choice in renal failure. Clearance is completely independent of renal and hepatic function. |
| Rocuronium & Vecuronium | Primarily hepatic metabolism and biliary excretion; Vecuronium 20-30% renal, Rocuronium 10-20% renal | 3-desacetylvecuronium (active, accumulates in renal failure) | Duration of action is moderately prolonged in ESRD. Monitor train-of-four (TOF); reverse with Sugammadex or Neostigmine/Glycopyrrolate. |
| Sugammadex | Exclusively Renal (95-98% unchanged) | None | Forms tight 1:1 encapsulation complex with Rocuronium. Complexes remain in circulation for prolonged periods in ESRD but do not dissociate; removed by high-flux hemodialysis. |
| Morphine | Hepatic glucuronidation | Morphine-6-Glucuronide (M6G): Potent $\mu$-agonist (accumulates $\rightarrow$ severe respiratory depression). Morphine-3-Glucuronide (M3G): Neurotoxic (hyperalgesia, myoclonus). | Avoid in renal failure / ESRD. |
| Hydromorphone | Hepatic glucuronidation | Hydromorphone-3-Glucuronide (H3G): Neurotoxic, accumulates in renal failure. | Use with caution at reduced doses; titrate carefully. |
| Meperidine | Hepatic N-demethylation | Normeperidine: Potent CNS stimulant (half-life 15-30 hours; accumulates in ESRD $\rightarrow$ seizures, tremors). | Strictly contraindicated in renal impairment. |
| Fentanyl, Sufentanil, Remifentanil | Fentanyl/Sufentanil: Hepatic; Remifentanil: Plasma esterases | No active metabolites | Opioids of choice in renal failure. No toxic metabolite accumulation. |
A 68-year-old woman with septic shock secondary to acute pyelonephritis is admitted to the ICU. Arterial blood gas and laboratory testing reveal: pH 7.22, PaCO2 28 mmHg, PaO2 88 mmHg, HCO3- 11 mEq/L, Na+ 138 mEq/L, K+ 4.8 mEq/L, Cl- 101 mEq/L, and serum Albumin 2.0 g/dL. Which statement accurately describes her acid-base status and compensation?
A 72-year-old male with chronic hypertension treated with Lisinopril 20 mg daily and acute severe osteoarthritis pain managed with Ketorolac 30 mg IV q6h arrives for emergent repair of an incarcerated inguinal hernia. Induction of general anesthesia results in a sustained reduction in mean arterial pressure to 55 mmHg. Which combination of glomerular hemodynamics best explains why this patient is at catastrophic risk for acute kidney injury?
On postoperative day 2 following complex aortic aneurysm repair, an oliguric patient has a urine output of 15 mL/h for 8 consecutive hours. Diagnostic testing demonstrates: Serum Creatinine 2.4 mg/dL (baseline 1.0 mg/dL), BUN 54 mg/dL, Urine Sodium 12 mEq/L, Urine Osmolality 580 mOsm/kg, and Fractional Excretion of Sodium (FENa) 0.6%. Urine microscopy reveals transparent hyaline casts without pigmented granular cylinders. What is the primary diagnosis and physiologic mechanism?